$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000106282213000036 Filed on November 12, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q4
Revenue	$1.410M	$238.0K	$218.0K
YoY Change	546.79%	-36.02%	-36.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.400M	$4.700M	$3.900M
YoY Change	-12.82%	6.82%	-2.5%
% of Gross Profit
Research & Development	$20.30M	$25.40M	$21.00M
YoY Change	-3.33%	32.35%	-25.27%
% of Gross Profit
Depreciation & Amortization	$700.0K	$600.0K	$900.0K
YoY Change	-22.22%	-45.45%	-18.18%
% of Gross Profit
Operating Expenses	$18.40M	$31.45M	$24.70M
YoY Change	-25.51%	6.87%	-26.71%
Operating Profit	-$16.98M	-$31.22M	-$24.49M
YoY Change	-30.69%	7.42%	-26.54%
Interest Expense	-$500.0K	$492.0K	-$500.0K
YoY Change	0.0%	-6.64%	0.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$11.00K	$100.0K
YoY Change	-100.0%	175.0%
Pretax Income	-$17.40M	-$31.70M	-$24.90M
YoY Change	-30.12%	7.46%	-26.33%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.41M	-$31.66M	-$24.87M
YoY Change	-29.99%	7.17%	-26.51%
Net Earnings / Revenue	-1235.04%	-13301.68%	-11409.63%
Basic Earnings Per Share
Diluted Earnings Per Share	-$237.1K	-$432.5K	-$343.4K
COMMON SHARES
Basic Shares Outstanding	513.5M shares	513.5M shares	512.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.7M	$150.8M	$222.8M
YoY Change	-42.24%	-26.94%	-20.8%
Cash & Equivalents	$37.50M	$19.58M	$30.42M
Short-Term Investments	$91.20M	$131.2M	$192.4M
Other Short-Term Assets	$4.636M	$7.257M	$6.349M
YoY Change	-26.98%	-19.4%	69.4%
Inventory
Prepaid Expenses
Receivables	$790.0K	$895.0K	$1.378M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$134.6M	$159.4M	$230.9M
YoY Change	-41.74%	-26.25%	-19.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.36M	$41.84M	$42.63M
YoY Change	-2.98%	-3.85%	-8.15%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$144.0K	$158.0K	$109.0K
YoY Change	32.11%	17.04%	-46.83%
Total Long-Term Assets	$139.6M	$140.1M	$140.8M
YoY Change	-0.88%	-1.17%	-2.68%
TOTAL ASSETS
Total Short-Term Assets	$134.6M	$159.4M	$230.9M
Total Long-Term Assets	$139.6M	$140.1M	$140.8M
Total Assets	$274.2M	$299.5M	$371.8M
YoY Change	-26.26%	-16.31%	-13.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.715M	$9.709M	$7.661M
YoY Change	26.81%	125.48%	26.8%
Accrued Expenses	$7.674M	$11.53M	$8.922M
YoY Change	-13.99%	-9.8%	-35.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.710M	$1.675M	$1.574M
YoY Change	8.64%	8.63%	9.08%
Total Short-Term Liabilities	$19.29M	$23.60M	$18.29M
YoY Change	5.52%	23.87%	-14.52%
LONG-TERM LIABILITIES
Long-Term Debt	$20.17M	$20.61M	$21.88M
YoY Change	-7.82%	-7.52%	-6.71%
Other Long-Term Liabilities	$32.39M	$37.39M	$32.28M
YoY Change	0.32%	20.28%	-41.46%
Total Long-Term Liabilities	$52.55M	$58.00M	$54.16M
YoY Change	-2.97%	8.68%	-31.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.29M	$23.60M	$18.29M
Total Long-Term Liabilities	$52.55M	$58.00M	$54.16M
Total Liabilities	$104.0M	$113.7M	$105.1M
YoY Change	-1.05%	8.25%	-20.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.004B	-$986.5M	-$899.8M
YoY Change	11.57%	12.75%	13.96%
Common Stock	$514.0K	$514.0K	$512.0K
YoY Change	0.39%	3.84%	6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.503M	$1.503M	$630.0K
YoY Change	138.57%	138.57%	82.61%
Treasury Stock Shares	814.0K shares	814.0K shares	380.0K shares
Shareholders Equity	$170.2M	$185.7M	$266.7M
YoY Change
Total Liabilities & Shareholders Equity	$274.2M	$299.5M	$371.8M
YoY Change	-26.26%	-16.31%	-13.64%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q4
OPERATING ACTIVITIES
Net Income	-$17.41M	-$31.66M	-$24.87M
YoY Change	-29.99%	7.17%	-26.51%
Depreciation, Depletion And Amortization	$700.0K	$600.0K	$900.0K
YoY Change	-22.22%	-45.45%	-18.18%
Cash From Operating Activities	-$21.80M	-$23.90M	-$20.50M
YoY Change	6.34%	-4.4%	-8.89%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$300.0K	-$100.0K
YoY Change	100.0%	200.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$40.00M	$20.50M	-$6.600M
YoY Change	-706.06%	75.21%	-136.07%
Cash From Investing Activities	$39.70M	$20.30M	-$6.700M
YoY Change	-692.54%	75.0%	-137.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-100.0K	0.000	36.80M
YoY Change	-100.27%	-100.0%	-77.04%
NET CHANGE
Cash From Operating Activities	-21.80M	-23.90M	-20.50M
Cash From Investing Activities	39.70M	20.30M	-6.700M
Cash From Financing Activities	-100.0K	0.000	36.80M
Net Change In Cash	17.80M	-3.600M	9.600M
YoY Change	85.42%	-72.09%	-93.84%
FREE CASH FLOW
Cash From Operating Activities	-$21.80M	-$23.90M	-$20.50M
Capital Expenditures	-$200.0K	-$300.0K	-$100.0K
Free Cash Flow	-$21.60M	-$23.60M	-$20.40M
YoY Change	5.88%	-5.22%	-8.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7661000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9709000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1378000	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	895000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8922000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11529000	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81533000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	83416000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	38000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1173205000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1166605000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5728000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4905000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5700000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1600000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2013Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2013Q3	us-gaap	Assets Assets	299458000	USD
CY2012Q4	us-gaap	Assets Assets	371778000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	230935000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	159362000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30423000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2194000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	70000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-908000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	285000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	873000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	15000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19581000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186309000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20759000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-165550000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10842000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	512000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29498000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85338000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86697000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31651000	USD
	us-gaap	Contracts Revenue ContractsRevenue	733000	USD
	us-gaap	Contracts Revenue ContractsRevenue	565000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	214000	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	238000	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	128000	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	685000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13910000	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13405000	USD
CY2013Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3274000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	10087000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	3079000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-35000000	USD
CY2012Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	30120000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29920000	USD
CY2013Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	32999000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	55033000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13709000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4716000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13123000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4396000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2013Q3	us-gaap	Goodwill Goodwill	44543000	USD
CY2013Q3	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4900000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6684000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1887000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-483000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-117000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-52000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	62000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5256000	USD
CY2013Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
	us-gaap	Interest Expense InterestExpense	1594000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	527000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	492000	USD
	us-gaap	Interest Expense InterestExpense	1494000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1535000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1437000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	44000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	136000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	158000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	105100000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	113748000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	371778000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	299458000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18285000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	23598000	USD
CY2013Q3	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	79000	USD
	us-gaap	Licenses Revenue LicensesRevenue	306000	USD
CY2012Q3	us-gaap	Licenses Revenue LicensesRevenue	158000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1574000	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1675000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21877000	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20609000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1277000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-444000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-91078000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59773000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74028000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69338000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-86712000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-29539000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-31658000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-85338000	USD
	us-gaap	Operating Expenses OperatingExpenses	84794000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	29432000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	31454000	USD
	us-gaap	Operating Expenses OperatingExpenses	86207000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-85395000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83923000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29060000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-31216000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	285000	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	7257000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6349000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	109000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	158000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	41000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32283000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37391000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	873000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	151776000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80954000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	379000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1506000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1055000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	874000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-111000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-146000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	142125000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	61070000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	108000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41838000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	874000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	185710000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	266678000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42634000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1068000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1167000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25400000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69419000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19192000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61584000	USD
CY2012Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2013Q3	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-986544000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-899832000	USD
CY2012Q3	us-gaap	Revenues Revenues	372000	USD
CY2013Q3	us-gaap	Revenues Revenues	238000	USD
	us-gaap	Revenues Revenues	812000	USD
	us-gaap	Revenues Revenues	871000	USD
CY2013Q3	us-gaap	Secured Debt SecuredDebt	22300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4905000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5728000	USD
CY2013Q3	us-gaap	Short Term Investments ShortTermInvestments	131629000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	192785000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1055000	USD
CY2013Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	185710000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	266678000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	297568000	USD
CY2012Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	252759000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-146000	USD
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	380000	shares
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	814000	shares
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1503000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	630000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	483693000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	512980000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	490049000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	513419000	shares
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	10087000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	3079000	USD
CY2012Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	5844000	USD
CY2013Q3	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1338000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	80808	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	1.98
	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	35000000	USD
	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	0	USD
CY2013Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	723000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2030000	USD
CY2012Q3	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	669000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2349000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3379000	USD
CY2013Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1027000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2875000	USD
CY2012Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	923000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
	lxrx	Symphony Base Payment Acceleration Of Expense SymphonyBasePaymentAccelerationOfExpense	4300000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	513517074	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-13-000036-index-headers.html	Edgar Link	pending
0001062822-13-000036-index.html	Edgar Link	pending
0001062822-13-000036.txt	Edgar Link	pending
0001062822-13-000036-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20130930.xml	Edgar Link	completed
lxrx-20130930.xsd	Edgar Link	pending
lxrx-20130930_cal.xml	Edgar Link	unprocessable
lxrx-20130930_def.xml	Edgar Link	unprocessable
lxrx-20130930_lab.xml	Edgar Link	unprocessable
lxrx-20130930_pre.xml	Edgar Link	unprocessable
lxrx930201310-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2013 Q4 Form 10-Q Financial Statement

#000106282213000036 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2013 Q4 Form 10-Q Financial Statement

#000106282213000036 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx